DNLI: Denali Therapeutics Inc

DNLI新闻

• 17:38 DNLI Gains 25.4% Year to Date: Should You Buy, Sell or Hold the Stock?
• 18:27 Denali Stock Falls as Partner Takeda Ends Collaboration Deal
• 12:00 Denali Solved A Major Challenge In Treating A Rare Genetic Disease. Now, Shares Are Flying.
• 23:15 Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome - Slideshow (NASDAQ:DNLI) 2026-03-27
• 18:25 Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up
• 12:30 FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease - Denali Therapeutics (NASDAQ:DNLI)
• 10:55 Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome Transcript
• 18:08 Denali Jumps, Pulling Regenxbio Higher, On Early FDA Approval
• 00:22 Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Virtual CNS Forum Transcript
• 15:32 Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?
• 12:28 Stifel sees rare disease stocks gaining after FDA official exit
• 20:55 Denali Therapeutics Inc. (DNLI) Presents at TD Cowen 46th Annual Health Care Conference Transcript
• 22:57 Jefferies重申Denali股票买入评级,看好基因疗法前景
• 22:55 Jefferies reiterates Denali stock Buy rating on gene therapy outlook
• 14:02 DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus
• 14:54 Wolfe Research首次覆盖Denali Therapeutics股票,评级为Peerperform